ARTICLE | Clinical News
Decitabine: Phase II
March 20, 2000 8:00 AM UTC
SUPG published in the Journal of Clinical Oncology data from a 66-patient international Phase II trial showing an overall response of 49 percent, with a 64 percent response in high risk patients. ...